The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects

The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00994006

Enrollment

Registered

2009-10-14

Start date

2010-01-31

Completion date

2011-03-31

Last updated

2011-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects, Hypomagnesemia

Keywords

Magnesium, nutrition, platelets, aggregation

Brief summary

The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is common in hospitalized patients, especially in the elderly with coronary artery disease (CAD) and/or those with chronic heart failure. Hypomagnesemia is associated with increased incidence of diabetes mellitus, metabolic syndrome, mortality rate from coronary artery disease (CAD) and all cause. Magnesium supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell death; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and adhesion. The data regarding the absorption difference between supplemental magnesium oxide and magnesium citrate in humans is spare.

Detailed description

Two oral preparations of magnesium are available in Israel: 1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany 2. Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel. The data regarding the absorption difference between the two supplemental magnesium preparations (magnesium oxide and magnesium citrate) in humans is spare. Primary objective: To find out the absorption of magnesium citrate compared to magnesium oxide in healthy subjects with no apparent heart disease.

Interventions

DIETARY_SUPPLEMENTMagnesium oxide

520 mg of elemental magnesium q.d.

DIETARY_SUPPLEMENTMagnesium citrate

Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age 20-70 years 2. Healthy subjects

Exclusion criteria

1. Chest pain 2. Diabetes mellitus 3. Documented coronary artery disease 4. Asthma or any lung disease 5. Chronic diarrhea 6. Chronic renal failure (serum creatinine\> 3 mg/dL) 7. Hypo or hyperthyroidism 8. Heart failure 9. On any chronic therapy/medications 10. Malabsorption 11. AV block 12. Pacemaker 13. Any malignancy 14. Obesity \> 30 kg/m2 body mass index 15. Smokers 16. Pregnancy 17. Alcohol or drug abuse 18. Any chronic inflammation 19. Refuse to sign inform consent

Design outcomes

Primary

Measure	Time frame
Intracellular magnesium levels will be assessed	30-day

Secondary

Measure	Time frame
Platelet function tests	30-day

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026